As of 17 Sept 2026, Lupin Ltd share price is ₹2,052.30. The stock opened at ₹2,052.30 and had closed at ₹2,047.20 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹1,900.30 and a high of ₹2,530.00. In terms of performance, Lupin Ltd share price has decreased by 11.09% over the past six months and has increased by 0.06% over the last year.
LUPIN Stock Price Chart
Lupin Ltd Overview
About LUPIN
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.
Lupin Ltd Historical Performance
LUPIN Futures & Options
Lupin Ltd Fundamentals
Lupin Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 19,825.43 | 17,141.55 | 14,773.23 | 11,350.09 | 11,922.09 |
| EBITDA | 8,522.90 | 5,569.31 | 3,565.79 | 1,173.92 | 426.13 |
| Net Profit | 6,366.56 | 3,972.96 | 2,326.09 | 425.21 | -188.70 |
| EPS | 129.18 | 87.10 | 51.10 | 9.35 | -4.16 |
Lupin Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 2,031.58 |
| Resistance 1 (R1) | 2,067.13 |
| Pivot Point | 2,051.52 |
Lupin Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 17-Jul-2026 | 07-May-2026 | 17-Jul-2026 | Final | ₹18.00 |
| 25-Jul-2025 | 14-May-2025 | 25-Jul-2025 | Final | ₹12.00 |
| 16-Jul-2024 | 06-May-2024 | 16-Jul-2024 | Final | ₹8.00 |
| 14-Jul-2023 | 09-May-2023 | 14-Jul-2023 | Final | ₹4.00 |
| 14-Jul-2022 | 19-May-2022 | 15-Jul-2022 | Final | ₹4.00 |
LUPIN Key Leadership Details
Last Updated: Mar 2026
| Name | Position |
|---|---|
| M D Gupta | Chairperson |
| Vinita Gupta | Chief Executive Officer |
| Nilesh Gupta | Managing Director |
Lupin Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,853.90+0.02% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,260.50+1.12% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,805.50-0.15% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Lupin Ltd today is ₹2,052.30 on NSE and ₹2,052.30 on BSE.
- The 52-week high of Lupin Ltd is ₹2,530.00, while the 52-week low is ₹1,900.30.
- The current market capitalisation of Lupin Ltd is approximately ₹93,611 crore.
- The P/E (Price-to-Earnings) ratio of Lupin Ltd is 22.56. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Lupin Ltd is 5.36. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Lupin Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for LUPIN on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Lupin Ltd has delivered a return of approximately 77.90%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Lupin Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 46.85% promoters, 7.58% FIIs, 24.65% DIIs, and 5.06% public shareholders.

